- Differential Diagnosis
Drug Information for CYLERT (pemoline) CS-IV (Abbott Laboratories): INDICATIONS AND USAGE
- CLINICAL PHARMACOLOGY
- INDICATIONS AND USAGE
- ADVERSE REACTIONS
- DOSAGE AND ADMINISTRATION
- HOW SUPPLIED
- Diseases/Conditions Related to CYLERT (pemoline) CS-IV (Abbott Laboratories)
- External Links Related to CYLERT (pemoline) CS-IV (Abbott Laboratories)
CYLERT (pemoline) is indicated in Attention Deficit Hyperactivity Disorder (ADHD). Because of its association with life threatening hepatic failure, CYLERT should not ordinarily be considered as first line therapy for ADHD (see BOXED WARNING).
CYLERT (pemoline) therapy should be part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.
- Drug Information Provided by National Library of Medicine (NLM).